Compare CSX Corporation (CSX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs GSK plc — how do they compare? CSX Corporation trades at $47.12 (market cap $87.70B), while GSK plc trades at $46.39 (market cap $91.88B). The key difference: CSX Corporation and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and GSK plc for 93 Days on average.
| CSX | GSK | |
|---|---|---|
Market Cap | $87.70B | $91.88B |
Volume | 6,980,781 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $53.21 | $61.18 |
52-Week Low | $33.68 | $43.24 |
Typical Hold Time | 55 Days | 93 Days |
Enterprise Value | $105.66B | $111.88B |
Dividend Yield | 1.18% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% with a bearish technical signal. The railroad operator shows mixed fundamentals with declining revenue from $14.9B in 2022 to $14.1B in 2025, though net income margins remain strong at 22.21%. Recent earnings show two beats and one miss, with Q3 2026 results pending. Analyst consensus is bullish with 59% buy ratings and a $51 price target, representing 9% upside from current levels.
CSX offers steady dividend income and pricing power in an irreplaceable freight network, but faces revenue pressure and elevated valuation multiples. The stock's investment case hinges on operational efficiency gains and freight volume recovery, balanced against economic sensitivity and competitive pressures in the transportation sector.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
